Quantbot Technologies LP Takes $3.83 Million Position in Bruker Corporation $BRKR

Key Points

• Quantbot Technologies LP has invested approximately $3.83 million in Bruker Corporation by acquiring 91,789 shares during the 1st quarter.
• The CEO, Frank H. Laukien, purchased 2,608 shares at a value of around $100,042, increasing his ownership to 38,462,171 shares.
• Bruker recently announced a quarterly dividend of $0.05 per share, reflecting a 0.6% yield and a payout ratio of 38.46%.

Quantbot Technologies LP purchased a new stake in Bruker Corporation (NASDAQ:BRKR - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 91,789 shares of the medical research company's stock, valued at approximately $3,831,000. Quantbot Technologies LP owned about 0.06% of Bruker as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Versor Investments LP purchased a new stake in Bruker in the first quarter valued at about $484,000. Sector Gamma AS increased its holdings in shares of Bruker by 33.3% in the first quarter. Sector Gamma AS now owns 211,970 shares of the medical research company's stock valued at $8,848,000 after purchasing an additional 53,000 shares during the period. Liontrust Investment Partners LLP acquired a new position in shares of Bruker in the first quarter valued at about $344,000. Fox Run Management L.L.C. acquired a new position in shares of Bruker in the first quarter valued at about $429,000. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of Bruker by 1,354.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock valued at $33,000 after purchasing an additional 745 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Bruker

In other Bruker news, CEO Frank H. Laukien purchased 2,608 shares of the firm's stock in a transaction on Friday, June 6th. The stock was bought at an average cost of $38.36 per share, with a total value of $100,042.88. Following the acquisition, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at approximately $1,475,408,879.56. This represents a 0.01% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 27.30% of the stock is owned by company insiders.

Bruker Stock Up 5.1%

BRKR traded up $1.74 on Friday, hitting $35.54. 1,939,915 shares of the company were exchanged, compared to its average volume of 3,459,438. Bruker Corporation has a twelve month low of $30.00 and a twelve month high of $72.94. The company has a market cap of $5.39 billion, a price-to-earnings ratio of 68.35, a price-to-earnings-growth ratio of 2.79 and a beta of 1.16. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The firm has a 50-day moving average price of $38.48 and a two-hundred day moving average price of $41.05.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The company's revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.52 earnings per share. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, equities analysts predict that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker's payout ratio is 38.46%.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on BRKR shares. UBS Group cut their price objective on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Stifel Nicolaus set a $40.00 target price on Bruker and gave the stock a "hold" rating in a report on Tuesday, August 5th. The Goldman Sachs Group dropped their target price on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Bank of America dropped their target price on Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Finally, Wells Fargo & Company dropped their target price on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Tuesday, August 5th. Five equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Bruker currently has a consensus rating of "Hold" and an average target price of $51.30.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.